Form 4: Revolution Medicines CFO Sells Shares to Cover Tax Obligations

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,261 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 18, 2024, Jack Anders, the Chief Financial Officer of Revolution Medicines, sold 1,261 shares of the company's common stock.
• The sale was executed at a price of $31.5832 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligations upon the vesting of restricted stock units (RSUs).
• The sale was an automatic sell-to-cover imposed by the terms of the RSU award, following the vesting of the RSUs solely to cover applicable withholding taxes.
• Following the transaction, Anders directly owns 101,959 shares, which includes 60,250 RSUs.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Sales of shares by company executives to cover tax obligations upon vesting of restricted stock units are a common practice.

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on shareholders due to the small volume of shares sold.

Key Dates